Breakout Setups
PVLA appears in our Breakout Setups screen. This means the stock shows strong technical strength, a constructive consolidation pattern, and enough volatility to support a potential breakout if price moves above resistance.
PALVELLA THERAPEUTICS INC (PVLA) Stock Price & Overview
NASDAQ:PVLA • US6979471090
Current stock price
127.12 USD
-3.08 (-2.37%)
At close:
125 USD
-2.12 (-1.67%)
Pre-Market:
The current stock price of PVLA is 127.12 USD. Today PVLA is down by -2.37%. In the past month the price decreased by -6.94%. In the past year, price increased by 484.19%.
PVLA Key Statistics
52-Week Range20.2 - 151.18
Current PVLA stock price positioned within its 52-week range.
1-Month Range108.63 - 138.83
Current PVLA stock price positioned within its 1-month range.
- Market Cap
- 1.819B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.70
- Dividend Yield
- N/A
PVLA Stock Performance
Today
-2.37%
1 Week
+2.96%
1 Month
-6.94%
3 Months
+37.56%
Longer-term
6 Months +81.86%
1 Year +484.19%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A
PVLA Stock Chart
PVLA Stock Screens
PVLA currently appears in the following ChartMill screener lists.
PVLA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to PVLA. When comparing the yearly performance of all stocks, PVLA is one of the better performing stocks in the market, outperforming 99.01% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
PVLA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to PVLA. While PVLA seems to be doing ok healthwise, there are quite some concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
PVLA Earnings
Next Earnings DateMay 13, 2026
Last Earnings DateMar 31, 2026
PeriodQ4 / 2025
EPS Reported-$1.07
Revenue Reported
EPS Surprise -15.20%
Revenue Surprise %
PVLA Forecast & Estimates
22 analysts have analysed PVLA and the average price target is 234.03 USD. This implies a price increase of 84.1% is expected in the next year compared to the current price of 127.12.
Analysts
Analysts84.55
Price Target234.03 (84.1%)
EPS Next Y-38%
Revenue Next YearN/A
PVLA Groups
Sector & Classification
PVLA Financial Highlights
Over the last trailing twelve months PVLA reported a non-GAAP Earnings per Share(EPS) of -3.7. The EPS increased by 68.81% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-41.72M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -70.04% | ||
| ROE | -149.07% | ||
| Debt/Equity | 0.63 |
Chartmill High Growth Momentum
EPS Q2Q%60.63%
Sales Q2Q%N/A
EPS 1Y (TTM)68.81%
Revenue 1Y (TTM)-100%
PVLA Ownership
Ownership
Inst Owners65.05%
Shares14.31M
Float10.79M
Ins Owners13.8%
Short Float %21.04%
Short Ratio5.82
PVLA Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.02 | 367.796B | ||
| AMGN | AMGEN INC | 15.37 | 189.224B | ||
| GILD | GILEAD SCIENCES INC | 15.72 | 172.517B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.4 | 110.97B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.97 | 79.171B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.19 | 42.718B | ||
| INSM | INSMED INC | N/A | 33.416B | ||
| NTRA | NATERA INC | N/A | 27.358B | ||
| BIIB | BIOGEN INC | 10.73 | 25.385B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.56 | 25.059B | ||
| MRNA | MODERNA INC | N/A | 20.21B | ||
| INCY | INCYTE CORP | 12.41 | 19.119B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.11B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PVLA
Company Profile
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The company is headquartered in Wayne, Pennsylvania and currently employs 14 full-time employees. The company went IPO on 2014-12-18. The firm is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The firm's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.
Company Info
IPO: 2014-12-18
PALVELLA THERAPEUTICS INC
353 W. Lancaster Avenue, Suite 200
Wayne PENNSYLVANIA US
Employees: 14
Phone: 14842531461
PALVELLA THERAPEUTICS INC / PVLA FAQ
What does PALVELLA THERAPEUTICS INC do?
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The company is headquartered in Wayne, Pennsylvania and currently employs 14 full-time employees. The company went IPO on 2014-12-18. The firm is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The firm's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.
Can you provide the latest stock price for PALVELLA THERAPEUTICS INC?
The current stock price of PVLA is 127.12 USD. The price decreased by -2.37% in the last trading session.
What is the dividend status of PALVELLA THERAPEUTICS INC?
PVLA does not pay a dividend.
How is the ChartMill rating for PALVELLA THERAPEUTICS INC?
PVLA has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Would investing in PALVELLA THERAPEUTICS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PVLA.
What is the employee count for PVLA stock?
PALVELLA THERAPEUTICS INC (PVLA) currently has 14 employees.
What is the next earnings date for PVLA stock?
PALVELLA THERAPEUTICS INC (PVLA) will report earnings on 2026-05-13.